HTG Molecular Diagnostics Company Description
HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine.
The company offers instruments; consumables; and software that automate sample processing and profiles various molecular targets.
Its marketed molecular profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq Oncology Biomarker Panel; HTG immune response panel; and HTG mouse mRNA tumor response panel.
The company distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally.
It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories.
The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011.
HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona. On May 21, 2025, the voluntary petition of HTG Molecular Diagnostics, Inc. for reorganization under Chapter 11 was converted to Chapter 7.
It had filed for Chapter 11 bankruptcy on June 5, 2023.
| Country | United States |
| Founded | 1997 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 54 |
| CEO | John Lubniewski |
Contact Details
Address: 3430 East Global Loop Tucson, Delaware 85706 United States | |
| Phone | 877 289 2615 |
| Website | htgmolecular.com |
Stock Details
| Ticker Symbol | HTGMQ |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US40434H3021 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| John L. Lubniewski | President, Chief Executive Officer and Director |
| Shaun D. McMeans | Senior Vice President, Chief Financial Officer, Secretary and Treasurer |
| Laura Lee Godlewski | Senior Vice President of Finance and Administration |
| Dr. Debra A. Gordon J.D., Ph.D. | Senior Vice President and Chief Legal Counsel |
| Dr. Patrick C. Roche | Senior Vice President of Research and Development |
| Dr. Stephen A. Barat Ph.D. | Senior Vice President of Therapeutics |
| Dr. Christina M. Carruthers Ph.D. | Vice President of Target Strategy and Early Development |
| Debrah Thompson | Vice President of Scientific Innovation |